Oncology with common sense: beyond biologistic and pharmacological models

dc.contributor.authorLastra, Rodrigo
dc.contributor.authorIranzo, Patricia
dc.contributor.authorBenitez Fuentes, Javier David
dc.contributor.authorCallejo, Ana
dc.contributor.authorCruellas, Mara
dc.contributor.authorGómez Ulla, Jacobo
dc.contributor.authorPimentel, Isabel
dc.contributor.authorPérez Gracia, José Luis
dc.contributor.authorRamos, Marta
dc.contributor.authorGil Moncayo, Francisco Luis
dc.contributor.authorÁlvarez Alejandro, María
dc.contributor.authorGascón, Marta
dc.contributor.authorMartínez Recio, Sergio
dc.contributor.authorRivero, Pilar
dc.contributor.authorBartolomé, Jorge
dc.contributor.authorLázaro Sánchez, Antonio David
dc.contributor.authorFernández Garay, David
dc.contributor.authorLuna Aguilar, Alicia de
dc.contributor.authorLorenzo Lorenzo, Isabel
dc.contributor.authorBrunet, Joan
dc.contributor.authorReguart, Noemí
dc.contributor.authorTrapani, Dario
dc.date.accessioned2026-06-29T10:09:44Z
dc.date.available2026-06-29T10:09:44Z
dc.date.issued2026-01-16
dc.date.updated2026-06-02T10:23:23Z
dc.description.abstractRapid advances in oncology have led to unprecedented pharmacological and technological complexity, yet these developments have not always translated into meaningful benefits for patients. Inspired by the Common Sense Oncology movement, this article reflects on the need to recalibrate cancer care beyond biologistic and industry-driven models. We argue for a broader, patient-centred vision of oncology that integrates social determinants of health, prevention, supportive and palliative care, shared decision-making and independent research alongside pharmacological innovation. Drawing on evidence from health economics, clinical research trends and public health, we highlight the paradox between rising oncology expenditures and limited gains in overall survival, quality of life and equity. We also discuss the growing influence of industry-sponsored research, the increasing reliance on surrogate endpoints, and the underfunding of non-pharmacological and psychosocial interventions. Finally, we propose concrete priorities for policymakers, clinicians and research institutions to ensure that oncology progress remains aligned with outcomes that truly matter to patients.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1754-6605
dc.identifier.pmid41777410
dc.identifier.urihttps://hdl.handle.net/2445/230253
dc.language.isoeng
dc.publisherEcancer Global Foundation
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3332/ecancer.2026.2059
dc.relation.ispartofecancermedicalscience, 2026, vol. 20, p. 2059
dc.relation.urihttps://doi.org/10.3332/ecancer.2026.2059
dc.rightscc-by (c) Lastra, Rodrigo et al., 2026
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationOncologiaca
dc.subject.classificationQuimioteràpia del càncerca
dc.subject.classificationQualitat de vidaca
dc.subject.otherOncologyen
dc.subject.otherCancer chemotherapyen
dc.subject.otherQuality of lifeen
dc.titleOncology with common sense: beyond biologistic and pharmacological models
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
ecancermedicalscience-2026-article-2059.pdf
Mida:
291.23 KB
Format:
Adobe Portable Document Format